PD-1/PD-L1免疫检查点抑制剂在晚期肝癌治疗中的临床研究进展  

Progress of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma

作　　者：王帅飞 魏巧琳 朱小宾[1] 孟欢欢 应杰[1] 弋东敏 汤磊磊 管燕[1] WANG Shuaifei;WEI Qiaolin;ZHU Xiaobin;MENG Huanhuan;YING Jie;YI Dongmin;TANG Leilei;GUAN Yan(Department of Pharmacy,Sir Run Run Shaw Hospital,Zhejiang University School of Medicine,Hangzhou 310016,China;Institute of Pharmacy,School of Medicine,Hangzhou Normal University,Hangzhou 311121,China;Department of Medical Records Management,Zhengzhou Central Hospital Affiliated to Zhengzhou University,Zhengzhou 450007,China;Department of Pharmacy,Hangzhou Normal University Affiliated Xiaoshan Hospital,Hangzhou 311200,China)

机构地区：[1]浙江大学医学院附属邵逸夫医院药学部,浙江杭州310016 [2]杭州师范大学药学院,浙江杭州311121 [3]郑州大学附属郑州中心医院病案管理科,河南郑州450007 [4]杭州师范大学附属浙江萧山医院药剂科,浙江杭州311200

出　　处：《中国医药指南》2023年第27期54-56,60,共4页Guide of China Medicine

基　　金：浙江省自然科学基金(LQ23H160004);浙江省医药卫生科技计划项目(2023RC250)。

摘　　要：肝癌已成为我国致死率第二的癌症,严重威胁人民生命健康。肝癌起病隐匿,临床发现时多数已处于晚期阶段,系统性抗肿瘤治疗成为晚期肝癌的主要治疗方式。近年来,肿瘤免疫微环境研究的进一步深入为肝癌治疗提供了新的思路和策略,尤其是PD-1/PD-L1免疫抑制剂在肝癌临床治疗中的应用越来越受到人们的关注,本文对近年来PD-1/PD-L1免疫抑制剂的临床研究进展进行系统性回顾和综述,以期为晚期肝癌的临床治疗提供一定的理论支撑和参考依据。Hepatocellular carcinoma(HCC)has emerged as the second leading cause of cancer-related mortality in China,which seriously threatens people's health.It was difficult to detect,and it was already in the advanced stage when it was discovered.Systemic anti-tumor treatment has become the primary treatment method for advanced HCC.In recent years,in-depth research on tumor immune micro-environment has provided new insights and strategies for the treatment of HCC,especially the application of PD-1/PD-L1 immune checkpoint inhibitors(ICIs)have attracted more and more attentions in clinical treatment of HCC.This paper reviews and summarizes the clinical progress of ICIs in recent years,to provide certain theoretical support and reference for the clinical treatment of advanced HCC.

关 键 词：PD-1/PD-L1 免疫检查点抑制剂 肝癌 免疫治疗 

分 类 号：R979.1[医药卫生—药品]